study to try to predict risk among new patients who have not yet undergone surgery.
The findings were published July 17 in the journal Science Translational Medicine.
Further investigation will be critical to assessing the new screening method’s “real-world generalizability,” said Dr. Cesar Castro, an assistant professor of medicine at Harvard Medical School, and director of the Cancer Program at MGH Center for Systems Biology in Boston. He was not part of the study.
But given that “a doctor is only as good as his or her intel,” Castro said the new screening test could prove to be an important advance in trying to get a better handle on true pancreatic cancer risk.
“Pancreatic cyst removal should not be confused with straightforward day surgeries,” Castro said. “Fatalities and
